Neuropathy and Neuropathic Pain in Patients with Type 2 Diabetes Mellitus Receiving Metformin - A Cross-Sectional Study from Navi Mumbai, Maharashtra
Abstract
BACKGROUND Metformin is reported to induce vitamin B12 deficiency and distinguishing peripheral neuropathy due to vitamin B12 deficiency from diabetic peripheral neuropathy can be challenging. The present study was conducted to assess and compare the clinical presentation of diabetic patients taking metformin with those not taking metformin using Toronto clinical scoring system (TCSS). METHODS This cross-sectional study included 60 patients with diabetes mellitus, 30 patients on metformin therapy (at least 6 months) and 30 patients not on metformin use. Clinical presentation of the patients was assessed using the TCSS. Patients were diagnosed according to the American diabetic association criteria. RESULTS The mean age of the patients in metformin and non-metformin group was 57.27 ± 9.38 and 58.63 ± 10.27 years respectively. Gender distribution was observed to be similar in both the study groups. Mean duration of diabetes mellitus was found to be similar in both the study groups (5.4 ± 1.01 vs 5.2 ± 1.27 years) and duration of peripheral neuropathy was also found to be similar in the two study groups (3.2 ± 1.6 vs 3.3 ± 1.5 years). Numbness was observed in maximum number of cases in both study groups. It was seen in 100 % (n = 30) patients on metformin drug while in 90 % (n = 27) patients without metformin. Pain accounts to be approximately 77 % (n = 23) and 24 % (n = 7) in patients on metformin and without metformin. Neuropathic symptoms and neuropathic reflex scoring…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 60 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.